BIOCON391.00

Biocon Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersSUNPHARMADRREDDYSYNGENEMANKINDGLENMARKLAURUSLABSALKEMLUPINMcap ₹63,381 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations14,755.715,261.716,927.017,321.1
Other Income865.51,208.2342.5317.3
Total Income15,621.216,469.917,269.517,638.4
Expenses
+ Cost of Materials Consumed5,071.94,276.75,277.65,477.7
+ Purchases of Stock-in-Trade682.7626.61,362.6907.4
+ Changes in Inventories-856.7294.2-949.5-631.9
+ Employee Benefit Expense2,664.13,144.43,508.03,591.0
+ Finance Costs974.4897.4990.3926.8
+ Depreciation & Amortisation1,568.81,687.01,956.72,049.1
+ Other Expenses3,895.03,753.54,273.04,440.5
Total Expenses14,000.214,679.816,418.716,760.6
EBITDA3,298.73,166.33,455.33,536.4
EBIT1,729.91,479.31,498.61,487.3
Profit
PBT before Exceptional Items1,621.01,790.1850.8877.8
+ Exceptional Items-11.696.5-402.9-399.2
Pretax Income1,609.41,886.6447.9478.6
+ Current Tax314.3369.3443.6492.7
+ Deferred Tax-86.987.9-364.5-430.5
Tax Expense227.4457.279.162.2
+ Share of Associates & JVs-84.20.00.00.0
Net Income1,297.81,429.4368.8416.4
+ Net Income — Continuing Ops1,382.01,429.4368.8416.4
+ Other Comprehensive Income386.7436.72,044.33,038.6
Total Comprehensive Income1,684.51,866.12,413.13,455.0
Net Income to Common1,022.51,013.3385.6495.3
Minority Interest275.3416.1-16.8-78.9
Per Share
Basic EPS8.558.462.823.40
Diluted EPS8.548.462.823.38
Other Comprehensive Income — detail
+ Other Comprehensive Income436.72,044.33,038.6
+ Items NOT to be Reclassified to P&L13.6-14.8426.71,153.0
+ Tax on Items NOT to be Reclassified2.622.361.0
+ Tax on Items NOT to be Reclassified — alt tag-3.0
+ Items to be Reclassified to P&L439.6407.01,548.71,907.4
+ Tax on Items to be Reclassified-47.1-91.2-39.2
+ Tax on Items to be Reclassified — alt tag69.5
Comprehensive Income — Owners of Parent1,291.31,369.62,299.33,385.8
Comprehensive Income — Non-controlling Interests393.2496.5113.869.2
Per Share — as-filed variants
Basic EPS — Continuing Operations8.558.462.823.40
Diluted EPS — Continuing Operations8.548.462.823.38
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit9,857.810,064.211,236.311,567.9
Gross Margin %66.8165.9466.3866.79
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)1,621.01,790.1850.8877.8
− Exceptional Items (reconciliation)-11.696.5-402.9-399.2
Net Income Adj (tax-effected)1,307.81,356.3700.5763.7
EPS Adj8.628.035.366.24
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value5.005.005.005.00
Paid Up Equity Capital600.3600.3810.5814.8
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.